Isosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT

Journal of Cardiac Failure

Volumn 13, Issue 5, 2007, Pages 331-339

  Cohn, Jay N ^a   Tam, S William ^b   Anand, Inder S ^a   Taylor, Anne L ^a   Sabolinski, Michael L ^b   Worcel, Manuel ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b NitroMed Inc   (United States)

Author keywords

Echocardiography; heart failure; mortality; nitric oxide; remodeling

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BUCINDOLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; NITRIC OXIDE; PLACEBO; SPIRONOLACTONE; VALSARTAN;

ADD ON THERAPY; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; DRUG DOSE TITRATION; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE;

ADULT; AFRICAN AMERICANS; AGED; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 34250793851     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.03.001     Document Type: Article

References (46)

1. Cohn J.N., Ferrari R., Sharpe N., and on Behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. JACC 35 (2000) 569-582
2. Wong M., Johnson G., Shabetai R., Hughes V., Bhat G., Lopez B., et al., for the V-HeFT VA Cooperative Studies Group. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure: Veterans Affairs Cooperative Studies V-HeFT I and II. Circulation 87 (1993) VI-65-VI-70
3. Cohn J.N., Johnson G.R., Shabetai R., Loeb H., Tristani F., Rector T., et al., for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 87 (1993) VI-5-VI16
4. Cintron G., Johnson G., Francis G., Cobb F., Cohn J.N., and for the V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation 87 (1993) VI-17-VI-23
5. Wong M., Staszewsky L., Latini R., Barlera S., Glazer R., Aknay N., et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. J Am Coll Cardiol 43 (2004) 2022-2027
6. Konstam M.A., Rouseau M.F., Kronenberg M.W., Udelson J.E., Melin J., Stewart D., et al. Effects of angiotensin converting enzyme inhibitor enalapril on the long-term progression of ventricular dysfunction in patients with heart failure. Circulation 85 (1992) 431-438
7. Greenberg B., Quinones M.A., Koilpillai C., Limacher M., Shindler D., Benedict C., et al., for the SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 91 (1995) 2573-2581
8. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., and Eichhorn E.J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. JACC 25 (1995) 1154-1161
9. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996) 2807-2816
10. Wong M., Staszewsky L., Latini R., Barlera S., Volpi A., Chiang Y.T., et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 40 (2002) 970-975
11. Cohn J.N., Archibald D.G., Ziesche S., Franciosa J.A., Harston W.E., Tristani F.E., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 314 (1986) 1547-1552
12. Carson P., Ziesche S., Johnson G., Cohn J.N., and for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Cardiac Failure 5 (1999) 178-187
13. Franciosa J.A., Taylor A.L., Cohn J.N., Yancy C.W., Ziesche S., Olukotun A., et al., for the A-HeFT Investigators. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 8 (2002) 128-135
14. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., et al., for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
15. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiography 2 (1989) 358-367
16. Lamas G.A., Vaughan D.E., Parisi A.E., and Pfeffer M.A. Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. Am J Cardiol 63 (1989) 1167-1173
17. Kono T., Sabbah H.N., Stein P.D., Brymer J.F., and Khaja F. Left ventricular shape as a determinant of functional mitral regurgitation in patients with severe heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 68 (1991) 355-359
18. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
19. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Chamber Quantification Writing Group. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography. J Am Soc Echocardiogr 18 (2005) 1440-1463
20. Cheng V., Kazanagra R., Garcia A., Lenert L., Krishnaswamy P., Gardetto N., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
21. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., and Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 39 (2002) 202-209
22. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al, on behalf of the African-American Heart Failure Trial Investigators. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007;115:1747-53.
23. Wong M., Johnson G., Shabetai R., Hughes V., Bhat G., Lopez B., et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure: Veterans affairs cooperative studies V-HeFT I and II. Circulation 87 (1993) VI-65-VI-70
24. Bristow M.R., O'Connell J.B., Gilbert E.M., French W.J., Leatherman G., Kantrowitz N.E., et al., Investigators for The Bucindolol. Heart failure/cardiac transplantation: dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 89 (1994) 1632-1642
25. Colucci W.S., Packer M., Bristow M.R., Gilbert M., Cohn J.N., Fowler M.B., et al., for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94 (1996) 2800-2806
26. Australia/New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol in patients with congestive heart failure due to ischaemic heart disease: final results from the ANZ heart failure research collaborative trial. Lancet 349 (1997) 212-218
27. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., et al. Congestive heart failure/myocardial disease: carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996) 1499-1506
28. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The Precise Trial. Circulation 94 (1996) 2807-2816
29. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The RESOLVD Pilot Study. Circulation 101 (2000) 378-384
30. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342 (1993) 1441-1446
31. Cohn J.N., Tognoni G., and for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
32. Anand I.S., Tam S.W., Rector T.S., Taylor A.L., Sabolinski M.L., Archambault W.T., et al. Influence of blood pressure on the effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 49 (2007) 32-39
33. Wong M., Staszewsky L., Volpi A., Latini R., Barlera S., and Hoglund C. Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in Heart Failure Trial (Val-HeFT). J Am Soc Echocardiography 15 (2002) 293-307
34. Maisel A. B-type natriuretic peptide levels: a potential "white count" for congestive heart failure. J Card Fail 7 (2001) 183-193
35. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
36. Latini R., Masson S., Anand I., Judd D., Maggioni A.P., Chiang Y.T., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
37. Latini R., Masson S., Wong M., Barlera S., Carretta E., Staszewsky L., et al., for the Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 119 (2006) 70 e23-30
38. Haga S.B., and Ginsburg G.S. Prescribing BiDil: is it black and white?. J Am Coll Cardiol 48 (2006) 12-14
39. Pierpont G.L., Cohn J.N., and Franciosa J.A. Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside. Chest 73 (1978) 8-13
40. Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. J N Y Acad Sci 811 (1997) 60-67
41. Münzel T., Kurz S., Rajagopalan S., Martin T., Berrington W.R., Thompson J.A., et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. J Clin Invest 98 (1996) 1465-1470
42. Bauer J.A., and Fung H.L. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 84 (1991) 35-39
43. Gogia H., Mehra A., Parikh S., Raman M., Uppal J.A., Johnson J.V., et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 26 (1995) 1575-1580
44. Prabhu S.D. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res 94 (2004) 1155-1157
45. Cohn J.N. Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation 48 (1973) 5-8
46. Konstam M.A., Udelson J.E., Anand I.S., and Cohn J.N. Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 9 (2003) 350-353